Join our daily newsletter At The Bell to receive exclusive market insights
The ASX is barrelling towards closing out 2024 with another red day on New Year’s Eve, but that doesn’t mean the year as a whole was a bloodbath – in fact, for much of the Aussie index it’s been quite the year to remember.
Even more so, some Australian companies have beaten the milestone marker (and by some distance, we may add), which was up 8.51% YTD across the board.
While nearly 10% up is a very respectable jump, we’re talking big, big leaps to close out the year and that means a dozen of the biggest winners across the bourse. These range from investment groups to biotech victors, and even (you guessed it) a buy now, pay later heavyweight that always draws HotCopper eyes.
Here are some of the many winners that made it through 2024 well in the green.
12) Hub24 Ltd (ASX:HUB) +97%
Opening our HotCopper winner picks, Hub24 is celebrating 2024 after the investment platform provider raked in more than $4 billion in recent quarters.
11) Pinnacle Investment Group (ASX:PNI) +127%
Pinnacle’s biggest move came after it grabbed stakes in two funds, one in the U.S. and one in the U.K., for what markets saw as a relatively cheap $142 million. It’s solid FY24 performance was another feather in the cap.
10) Telix Pharmaceuticals (ASX:TLX) +144%
Big wins for Telix came when the radiopharmaceuticals company updated investors on its Illucix sales; there had been strong growth again. Regulatory approvals also helped.
9) Sigma Healthcare (ASX:SIG) +162%
Comeback kid Sigma Healthcare rebounded in 2024 with aplomb, locking in a bumper merger with Chemist Warehouse (which is expected to wrap up next year) after a speed bump saw them lose several contracts.
8) Pro Medicus Limited (ASX:PME) +168%
It was all contracts, contracts, contracts for Pro Medicus (including one bagged right before the finish line) that helped the health imaging company more than double its value.
7) Spartan Resources (ASX:SPR) +172%
High-grade gold hits boasting “visible gold” in November accounted for a lot of Spartan’s strong 2024 movement, though wins at the miner’s Dalgaranga Pepper target, thanks to several great intercept results, popped up in the middle of the year too.
6) Life360 Inc (ASX:360) +205%
Life360 has continued to win at the fundamentals, though its app was perhaps the biggest motivator for price spikes – more and more Aussie families are downloading the GPS application that helps keep each other safe.
5) NUIX Limited (ASX:NXL) +236%
Opening the top five is NUIX, which may have added more than double its value simply because it stayed out of the negative headlines more in 2024. With the tech company putting several issues behind it through this calendar year – and therefore being able to focus on market quality more – investors flocked in.
4) IperionX Limited (ASX:IPX) +328%
The heavy push into titanium paid off for IperionX this year, especially after it finished work on its HAMR furnace in Virginia; a more than 300% bump reflected the positive work.
3) Findi Limited (ASX:FND) +364%
Findi is an interesting one on this list because it’s so heavily owned by individual investors and moves wildly in the market at times – all of which is to say it paid in spades for those retail investors in 2024 with a mega price spike. Findi on Tuesday was trading at $4.77 a share; more than $3.50 up YTD.
2) Zip Co Ltd (ASX:ZIP) +372%
Zip Co may have been pipped to the top spot by nearly 500%, but that’s no fault on the buy now, pay later company. If Sigma was a comeback win, Zip’s was a monumental rise from the dead. This time last year the financial services company was trading at just above 60 cents; it’s closing out December at $2.96 a share.
1) Mesoblast (ASX:MSB) +835%
The big winner in 2024 was Melbourne medicine company Mesoblast – which unsurprisingly, was the third-most-watched stock on HotCopper forums this year – and it’s rocket-ship-sized bull run through the last twelve months.
Most recently, the seemingly unstoppable biotech company saw a stock price hike again following long-awaited FDA approval ahead of its U.S. expansion.
Today, at around 11.38am today, shares in Mesoblast are selling at $3.19 each.
Join the discussion: See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
